anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an inactivating agent for causative viruses of diseases in livestock animals, etc., containing specific polyhexamethylenebiguanidines as an active ingredient and capable of effectively inactivating viruses without affecting humans, animals as well as plants and effectively preventing viral diseases. CONSTITUTION:An inactivating agent containing polyhexamethylenebiguandine having repeating units expressed by the formula, about 700-1,300, preferably 900-1,100 average molecular weight and antimicrobial activity against bacteria or salt thereof, e.g. hydrochloride, etc., as an active ingredient. A carrier or adjuvant is added to the above-mentioned active ingredient to prepare a solution agent or dust, which is used by directly spraying or applying to livestock animals, barns thereof, tools used therefor, instruments, materials, clothes, hands fingers, etc., ingredient is normally 0.01-30wt.%. The agent is useful for herpesviruses, coronatiruses, reoviruses, poxviruses, etc., as the above-mentioned viruses. Furthermore, cytotoxicity to human or animal dermal cells is low.
PURPOSE:To obtain a new compound capable of exhibiting remarkable enzyme- inhibiting activity against casein kinase II and useful as an antitumor agent. CONSTITUTION:A compound of the formula or its salt. This compound is obtained by inoculating a microorganism belonging to the genus Pseudorobillarda sp. or its variant (FERM P-13325), e.g. Pseudobillarda sp. F26668 into a nutrient source-containing medium and culturing the microorganism under aerobic conditions, harvesting the cultured mixture from the bacterial cell by normal separation means and separating and purifying the cultured product. Properties of the compound of the formula: Appearance, pale yellow solid; molecular formula, C13H10O5; solubility, readily soluble in acetone, methanol and ethyl acetate and sparingly soluble in chloroform and water and insoluble in hexane; discrimination of acidic, neutral or basic substance, acidic substance; Rf value, 0.43 (using 'Kiesel gel 60F254(R)' manufactured by Merck & Co., Inc. and developed using chloroform/methanol); color reaction, positive to iodine reaction and molybdophosphoric acid reaction and negative to ninhydrin reaction.
Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.
In the absence of an adequate drainage of the anterior sector (AS) veins, the consequent venous congestion in the RL graft may result in impaired graft regeneration, immediate liver dysfunction, and graft loss even in a liver graft of adequate size \[2\]. To overcome this problem, Lee et al. \[3\] introduced the concept of modified RL graft in which the branches of the middle hepatic vein (MHV) was drained using interposition vascular grafts. Although, the issue of when and how the MHV branches should be drained has been controversial since then, reconstruction of segment 5 and 8 veins using an interposition graft has become a standard procedure during RL LDLT. The vascular graft of choice in this procedure has been cryopreserved homologous vein graft, which provides excellent patency with low infection risk. However, such grafts are often unavailable, particularly in programs where deceased donors are scarce and surgeons must rely on synthetic grafts such as expanded polytetrafluoroethylene (ePTFE) and polyethylene terephthalate (Dacron®). Since we have developed an "intent-to-drain" policy in our LDLT program, we have been using Dacron grafts exclusively \[4\]. Although, complications such as early graft thrombosis, graft infection, and hollow viscous migration remain as major concerns, the safety and efficacy of both ePTFE and Dacron grafts in LDLT has been proven \[5, 6\]. However, to date, none of the previous studies have specifically compared these two different prosthetic materials, addressing graft patency and complication rates in patients undergoing LDLT. The aim of our study is to compare AS venous outflow reconstruction using ePTFE vs. Dacron grafts for their patency and infection rates and outcomes with respect to graft and patient survival in RL LDLT.
PURPOSE:To prepare a carcinostatic enzyme, by treating a proteinase produced in the emergence of silkworm moth with a slightly acidic organic acid, thereby purifying the enzyme to a cathepsin-type oxidase. CONSTITUTION:The chrysalis in the cocoon 1 emerges 4 by dissolving the sericin and fibroin constituting the cocoon layer by the enzyme excreted from the chrysalis. After emergence, the part 3 of the cocoon 1 contacting with the emergency enzyme is cut off at the line 2 to obtain a piece of cocoon 6 containing the emergency enzyme. The cocoon 6 is put into the extraction vessel 5 and immersed in tepid water at 30-35 deg.C to extract the emergency enzyme which is a proteinase. The extracted liquid is transferred to the stirring tank 7 and chemically treated with a slightly acidic organic acid 10 in a manner to prevent the enzyme from inactivation. The treated enzyme is purified in the purifying tank 8 and activated as a cathepsin-type oxidase 9 to obtain the objective carcinostatic enzyme solution.
Nausea, abdominal fullness and bloating are the most common adverse reactions (occurring in up to 50% of patients) to administration of PEG-3350 and Electrolytes for Oral Solution. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient and subside rapidly. Isolated cases of urticaria, rhinorrhea, dermatitis and (rarely) anaphylactic reaction have been reported which may represent allergic reactions. 

Published literature contains isolated reports of serious adverse reactions following the administration of PEG-ELS products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and “butterfly-like” infiltrates on chest X-ray after vomiting and aspirating PEG.
OBJECTIVE: To construct a predictive model to direct the dissection of the central lymph nodes in papillary thyroid cancer (PTC) with BRAF V600E mutation by identifying the risk variables for central lymph node metastases (CLNM).
METHODS: Data from 466 PTC patients with BRAF V600E mutations underwent thyroid surgery was collected and analyzed retrospectively. For these patients, we conducted univariate and multivariate logistic regression analysis to find risk variables for CLNM. To construct a nomogram, the independent predictors were chosen. The calibration, discrimination, and clinical utility of the predictive model were assessed by training and validation data.
RESULTS: CLNM was present in 323/466 PTC patients with BRAF V600E mutations. By using univariate and multivariate logistic regression, we discovered that gender, age, tumor size, multifocality, and pathological subtype were all independent predictors of CLNM in PTC patients with BRAF V600E mutations. A predictive nomogram was created by combining these variables. In both training and validation groups, the nomogram demonstrated great calibration capacities. The training and validation groups' areas under the curve (AUC) were 0.772 (specificity 0.694, sensitivity 0.728, 95% CI: 0.7195-0.8247) and 0.731 (specificity 0.778, sensitivity 0.653, 95% CI: 0.6386-0.8232) respectively. According to the nomogram's decision curve analysis (DCA), the nomogram might be beneficial. As well, an online dynamic calculator was developed to make the application of this nomogram easier in the clinic.
CONCLUSION: An online nomogram model based on the 5 predictors included gender, age, pathological subtype, multifocality, and tumor size was confirmed to predict CLNM and guide the central lymph nodes dissection in PTC patients with BRAF V600E mutations.
AIM: To investigate the possible relationship between intracranial aneurysms and brain neoplasms.
MATERIAL AND METHODS: A comprehensive literature review involving a search of the databases PubMed and Embase to identify relevant articles was conducted in March 2021. The initial search retrieved 451 articles. After deduplication and screening of abstracts, 56 articles were selected. After reading of the full texts, 19 articles were included in the review.
RESULTS: There insufficient evidence to support that people with brain neoplasms have a higher incidence rate of IAs. However, the prevalence of IAs appears to be higher in patients with pituitary tumors than in the general population. The key factors affecting prognosis were tumor type in patients with unruptured aneurysms and progression of subarachnoid hemorrhage in individuals with ruptured aneurysms. Treatment should be individualized according to patient age, tumor pathology, location, and aneurysm rupture risk.
CONCLUSION: There is a lack of evidence to affirm that the existence of brain neoplasm plays a role in the formation and rupture of intracranial aneurysms. Additionally, there is insufficient evidence to confirm a greater prevalence of intracranial aneurysms in individuals with brain tumors. The association of these two disorders does not appear to worsen patient outcome. Prognosis depends on tumor pathology for malignant cases and on subarachnoid hemorrhage in patients with ruptured aneurysms.
Participants will receive the DLX of GSK3494245 in the fed state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fasted state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
The invention discloses an immunological competence improving acid degradation product of polysaccharides of stems and leaves of abelmoschus esculentus and a method for preparing the immunological competence improving acid degradation product. The acid degradation product of the polysaccharides of the stems and leaves of the abelmoschus esculentus comprises mannose, glucose, galactose and arabinose. A molar ratio of the mannose to the glucose to the galactose to the arabinose is 0.33:17.03:1.00:0.41. The molecular weight of the acid degradation product of the polysaccharides of the stems and leaves of the abelmoschus esculentus is 715.17 kDa. The method includes optimizing extraction and separation technologies via large quantities of experiments; acquiring crude polysaccharides by the aid of water extraction and alcohol precipitation processes; removing protein; purifying the crude polysaccharides by the aid of DEAE-52 cellulose resin to obtain the high-purity polysaccharides of the stems and leaves of the abelmoschus esculentus; acquiring the acid degradation product of the polysaccharides of the stems and leaves of the abelmoschus esculentus by means of acid hydrolysis. The immunological competence improving acid degradation product and the method have the advantages that waste stem and leaf resources of the abelmoschus esculentus can be sufficiently utilized, accordingly, waste can be turned into wealth, the immunological competence improving acid degradation product of the polysaccharides of the stems and leaves of the abelmoschus esculentus can be prepared, traditional Chinese medicine resources can be sustainably applied, and the immunological competence improving acid degradation product and the method have excellent economic value.
"The data collection tools will be implemented during face-to-face interviews with participants. Interview durations will vary between 45 to 90 minutes. Interviews with individuals who accept the invitation to participate will be conducted in public places such as cafes, parks, and other community areas in the Beyoğlu district. The data collection process, initiated after ethical approval, will be concluded upon reaching a sufficient number of participants. Homeless individuals contacted through the 'Çorbada Tuzun Olsun Derneği' will be informed about the research and invited to participate. Individuals with neurological or psychiatric conditions that hinder communication and collaboration will not be included in the study. Fourteen homeless individuals aged 18 or older, literate, able to communicate and collaborate, and currently living on the European side of Istanbul will be included in the study. Data collection instruments for the study include a Demographic Information Form, Semi-Structured Interview Guide, Canadian Occupational Performance Measure, Occupational Justice Health Questionnaire, World Health Organization Quality of Life Scale Short Form, and Occupational Balance Questionnaire."
The present invention discloses a feed additive and an injection of a yolk antibody resisting the blue-ear disease in pig and a preparation method thereof. The feed additive of the yolk antibody resisting the blue-ear disease in pig is extracted and prepared by the collected yolk antibody of the immunized laying hens which are immunized by a bacterin for the blue-ear disease in pig. The injection of the yolk antibody resisting the blue-ear disease in pig is extracted and prepared by the collected yolk antibody of the immunized laying hens which are immunized by a bacterin for the blue-ear disease in pig. The injection of the yolk antibody resisting the blue-ear disease in pig prevents the blue-ear disease in pig by improving the antibody level of a pig organism to the blue-ear disease in pig. The present invention has beneficial effects that the feed additive of the yolk antibody resisting the blue-ear disease in pig is convenient for feeding and is very suitable for pig. The injection of the yolk antibody resisting the blue-ear disease in pig is used after the pig catches the disease, which has faster medicinal effect. The feed additive and a injection of a yolk antibody resisting the blue-ear disease in pig and the preparation method thereof has obvious curative effect, low cost, fast acting, no toxic and side effect, no drug-resistant strain which can be produced, simple preparation, wide raw material source, convenient use and easy popularization and can not produce drug-resistant strain.
Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
The derivs. are obtd. by reaction of an amine of formula (I), in which R2 is lower alkyl, phenyl or phenyl-alkyl, with a cpd. of formula (II), in which R1 is H, lower alkoxy, nitro or halogen. Reaction is carried out in an inert solvent, in presence of sodium hydride and N,N-methylphenylamino triphenyl phosphonium iodide at between ambient temp. and b.pt.
AIMS: Bacterial infection activates neutrophils to release neutrophil extracellular traps (NETs) in bacterial biofilms of periprosthetic joint infections (PJIs). The aim of this study was to evaluate the increase in NET activation and release (NETosis) and haemostasis markers in the plasma of patients with PJI, to evaluate whether such plasma induces the activation of neutrophils, to ascertain whether increased NETosis is also mediated by reduced DNaseI activity, to explore novel therapeutic interventions for NETosis in PJI in vitro, and to evaluate the potential diagnostic use of these markers.
METHODS: We prospectively recruited 107 patients in the preoperative period of prosthetic surgery, 71 with a suspicion of PJI and 36 who underwent arthroplasty for non-septic indications as controls, and obtained citrated plasma. PJI was confirmed in 50 patients. We measured NET markers, inflammation markers, DNaseI activity, haemostatic markers, and the thrombin generation test (TGT). We analyzed the ability of plasma from confirmed PJI and controls to induce NETosis and to degrade in vitro-generated NETs, and explored the therapeutic restoration of the impairment to degrade NETs of PJI plasma with recombinant human DNaseI. Finally, we assessed the contribution of these markers to the diagnosis of PJI.
RESULTS: Patients with confirmed PJI had significantly increased levels of NET markers (cfDNA (p < 0.001), calprotectin (p < 0.001), and neutrophil elastase (p = 0.022)) and inflammation markers (IL-6; p < 0.001) in plasma. Moreover, the plasma of patients with PJI induced significantly more neutrophil activation than the plasma of the controls (p < 0.001) independently of tumour necrosis factor alpha. Patients with PJI also had a reduced DNaseI activity in plasma (p < 0.001), leading to a significantly impaired degradation of NETs (p < 0.001). This could be therapeutically restored with recombinant human DNaseI to the level in the controls. We developed a model to improve the diagnosis of PJI with cfDNA, calprotectin, and the start tail of TGT as predictors, though cfDNA alone achieved a good prediction and is simpler to measure.
CONCLUSION: We confirmed that patients with PJI have an increased level of NETosis in plasma. Their plasma both induced NET release and had an impaired ability to degrade NETs mediated by a reduced DNaseI activity. This can be therapeutically restored in vitro with the approved Dornase alfa, Pulmozyme, which may allow novel methods of treatment. A combination of NETs and haemostatic biomarkers could improve the diagnosis of PJI, especially those patients in whom this diagnosis is uncertain.
Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume a combination of whole almonds and walnut pieces, a total of 110 g per day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Walnuts and almonds will be provided to participants for the duration of the study.
This study will be conducted to answer the question whether vaccination during chemotherapy induces an adequate antibody response in oncology patients. Moreover, the effect of the timing of the vaccination during a chemotherapy cycle will be evaluated. In the mamma carcinoma patients, the effect of early versus late vaccination during a chemotherapy cycle will be studied. It was chosen to vaccinate in the early group at day 4 +/- 1 day; the immediate influence of the chemotherapy on the vaccination response is expected to have passed by then and patients will not already have their nadir. Late vaccination was defined as vaccination on day 16 +/- 1 day of the cycle. It is expected that the white blood cell and platelet counts by then are normalised.

In order to define a relatively homogenous patient population with mamma carcinoma, in this study patients will be recruited who are treated in the adjuvant setting with FEC-containing regimens (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamid 500 mg/m2). The results of vaccination in these immunocompromised groups will be compared to the serological response to vaccination in persons who receive the influenza vaccination due to heart failure. Studies have shown that, although cytotoxic T-cell responses might be diminished, the rise in haemagglutinin inhibition titres in patients with heart failure vaccinated against influenza can be compared to the response to vaccination in otherwise healthy persons. These patients with heart failure will therefore be used as a control group. Patients with heart failure who are on treatment with immunosuppressives like prednisolone will not be included, because prednisolone diminishes the response to vaccination. The heart failure patients will be vaccinated according to the standard influenza vaccination protocol in the Netherlands.
Various agents and additives for cross-linking treatments are identified in disclosed studies. The characteristics of the various agents and additives may be advantageously employed in formulations applied in cross-linking treatments of the eye. In some embodiments, riboflavin is combined with Iron(II) to enhance the cross-linking activity generated by the riboflavin. In other embodiments, cross-linking treatments employ an Iron(II) solution in combination with a hydrogen peroxide pre-soak. In yet other embodiments, 2,3-butanedione is employed to increase the efficacy of corneal cross-linking with a photosensitizer, such as riboflavin. In further embodiments, folic acid is employed in combination with a photosensitizer, such as riboflavin, to enhance cross-linking activity. In yet further embodiments, 2,3-butanedione, folic acid, a quinoxaline, a quinoline, dibucaine, Methotrexate, menadione, or a derivative thereof is applied as a cross-linking agent.
This study will be conducted in compliance with the tenets of the Declaration of Helsinki and the Institutional Review Board of He Eye Specialist Hospital, Shenyang, China \[ethics approval number:

In recent years, the prevalence of myopia has significantly increased nationwide, The incidence rate of myopia among adolescents in China has risen significantly, causing blurred vision. Severe myopia can cause complications that threaten vision, such as glaucoma and macula disease. It would be highly undesirable to increase the social burden. Myopia can be corrected by orthokeratology (OK) and spectacles. It has been shown in numerous researches that orthokeratology lens are recognized as one of the effective methods in the treatment of myopia, has been widely used nationwide. In current years, the clinical treatment of myopia by OK lens in adolescents are increasingly confirmed to prevent the progression. Traditional OK lenses change refractive power by reshaping the corneal Epithelium (leading to the redistribution of corneal epithelium). As the overnight OK lens directly contact the ocular surface, the patients may endure symptoms and signs of dry eye disease (DED), which may even have some impact on the health of the ocular surface, including potential complications such as Keratitis. In addition, corneal staining often has occurred in ook wearers. According to previous studies, it has shown that wearing contact lens will affect the tear film stability, damage the function of the meibomian gland, tear film thinning, its affect ocular inflammation. Recent studies have also shown that OK continuous wearing has the least impact at 12 months. In order to ensure the safety of long-term wearing ok lenses in children and adolescents, the effect of OK lens on tear film and meibomian gland demonstrated further exploration.

The aim of this study is to evaluate the effect of OK on the ocular surface and meibomian gland function in children and adolescents. To assess the effect of OK on ocular surface and meibomian gland function in children and adolescents, so as to improve the application of the clinical.
After trial week five the Groups must cross-over. Group L will then receive treatment for five weeks (trial week 6-11) and Group E will act as follow up group.
Standard clinic-based CSC model treatment. Treatment will be delivered largely in clinic for 12 months.